NASDAQ:PULM

Pulmatrix Stock Forecast, Price & News

$1.02
+0.01 (+0.99 %)
(As of 06/23/2021 03:59 PM ET)
Add
Compare
Today's Range
$1.00
$1.02
50-Day Range
$0.83
$1.14
52-Week Range
$0.82
$3.04
Volume2,125 shs
Average Volume1.83 million shs
Market Capitalization$57.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38
30 days | 90 days | 365 days | Advanced Chart
Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.


Pulmatrix logo

About Pulmatrix

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

895th out of 2,105 stocks

Pharmaceutical Preparations Industry

434th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

Is Pulmatrix a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Pulmatrix stock.
View analyst ratings for Pulmatrix
or view top-rated stocks.

What stocks does MarketBeat like better than Pulmatrix?

Wall Street analysts have given Pulmatrix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pulmatrix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pulmatrix?

Pulmatrix saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 830,600 shares, a decline of 17.8% from the May 13th total of 1,010,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.5% of the company's shares are short sold.
View Pulmatrix's Short Interest
.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Pulmatrix
.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) announced its earnings results on Tuesday, May, 11th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company had revenue of $1.39 million for the quarter. Pulmatrix had a negative net margin of 166.28% and a negative trailing twelve-month return on equity of 63.93%.
View Pulmatrix's earnings history
.

How has Pulmatrix's stock price been impacted by COVID-19?

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PULM stock has decreased by 26.8% and is now trading at $1.01.
View which stocks have been most impacted by COVID-19
.

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix shares reverse split on the morning of Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PULM?

1 brokers have issued 12-month price objectives for Pulmatrix's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Pulmatrix's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 395.0% from the stock's current price.
View analysts' price targets for Pulmatrix
or view top-rated stocks among Wall Street analysts.

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the following people:
  • Mr. Teofilo David Raad, Pres, CEO & Director (Age 50, Pay $702.97k)
  • Ms. Michelle S. Siegert, VP of Fin. and Principal Financial & Accounting Officer (Age 60, Pay $390.34k)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 72)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 60)
  • Dr. Alexander M. Klibanov Ph.D., Founder (Age 71)
  • Mr. David J. Maki J.D., Advisor (Age 63)

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.25%), BlackRock Inc. (2.63%), Geode Capital Management LLC (0.52%), Goldman Sachs Group Inc. (0.25%), Northern Trust Corp (0.19%) and Millennium Management LLC (0.17%).
View institutional ownership trends for Pulmatrix
.

Which major investors are selling Pulmatrix stock?

PULM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Hussman Strategic Advisors Inc..
View insider buying and selling activity for Pulmatrix
or view top insider-selling stocks.

Which major investors are buying Pulmatrix stock?

PULM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., Millennium Management LLC, Northern Trust Corp, Citadel Advisors LLC, Citadel Advisors LLC, and UBS Group AG.
View insider buying and selling activity for Pulmatrix
or or view top insider-buying stocks.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.01.

How much money does Pulmatrix make?

Pulmatrix has a market capitalization of $56.81 million and generates $12.63 million in revenue each year. The biotechnology company earns $-19,310,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Pulmatrix have?

Pulmatrix employs 20 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is www.pulmatrix.com.

Where are Pulmatrix's headquarters?

Pulmatrix is headquartered at 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.